Annelies E De Weerd

Dr. Annelies E De Weerd


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2018 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
AWAnnelies E De Weerd
Annelies E De Weerd
MBMichiel G.H. Betjes
Michiel G.H. Betjes
Background and objectives: ABO blood group–incompatible kidney transplantation is considered a safe procedure, with noninferior outcomes in large cohort studies. Its contribution to living kidney transplantation programs is substantial and growing. Outcomes compared with center-matched ABO blood group–compatible control patients have not been ascertained. Design, setting, participants, & measurements: Comprehensive searches were conducted in Embase, Medline, Cochrane, Web-of-Science, and Google Scholar. Meta-analyses Of Observational Studies in Epidemiology study guidelines for observational studies and Newcastle Ottawa bias scale were implemented to assess studies. Meta-analysis was performed using Review Manager 5.3. A subgroup analysis on antibody removal technique was performed. Results: After identifying 2728 studies addressing ABO-incompatible kidney transplantation, 26 studies were included, describing 1346 unique patients who were ABO-incompatible and 4943 ABO-compatible controls. Risk of bias was low (all studies ≥7 of 9 stars). Baseline patient characteristics revealed no significant differences in immunologic risk parameters. Statistical heterogeneity of studies was low (I2 0% for graft and patient survival). One-year uncensored graft survival of patients who were ABO-incompatible was 96% versus 98% in ABO-compatible controls (relative risk, 0.97; 95% confidence interval, 0.96 to 0.98; P<0.001). Forty-nine percent of reported causes of death in patients who were ABO-incompatible were of infectious origin, versus only 13% in patients who were ABO-compatible (P=0.02). Antibody-mediated rejection (3.86; 95% confidence interval, 2.05 to 7.29; P<0.001), severe nonviral infection (1.44; 95% confidence interval, 1.13 to 1.82; P=0.003), and bleeding (1.92; 95% confidence interval, 1.36 to 2.72; P<0.001) were also more common after ABO-incompatible transplantation. Conclusions: ABO-incompatible kidney transplant recipients have good outcomes, albeit inferior to center-matched ABO-compatible control patients.

29 July 2014 in Transplant International
Verified
Journal Article
Open access
PDF file
AWAnnelies E De Weerd
Annelies E De Weerd
MAMadelon van Agteren
Madelon van Agteren
FLFrank W. Leebeek
Frank W. Leebeek
JIJan N.M. Ijzermans
Jan N.M. Ijzermans
WWWillem Weimar
Willem Weimar
MBMichiel GH Betjes
Michiel GH Betjes
Pretransplant removal of antiblood group ABO antibodies is the cornerstone of all current ABO‐incompatible (ABOi) transplantation programmes. In our protocol, plasmapheresis (PP) is performed with a plasmafilter followed by immunoadsorption (IA) of anti‐ABO antibodies. The bleeding complications of this technique are not known. We analysed the data of all 65 consecutive ABOi kidney transplantations between March 2006 and October 2013 and compared these with matched 130 ABO‐compatible (ABOc) kidney transplantations. Cases differed from controls in the pre‐operative regimen, which included IA‐PP and rituximab, tacrolimus, mycophenolate mofetil, prednisone and immunoglobulines. Data on platelet count, blood loss and red blood cell (EC) transfusions during 48 h postoperatively were collected. ABOi patients received EC transfusions more frequently than controls (29% vs. 12%, P = 0.005). Intra‐operative blood loss was higher (544 vs. 355 ml, P < 0.005) and they experienced more major bleeding (≥3 EC within 24 h, 15% vs. 2%, P < 0.0005). Platelet count decreased by 28% after the pre‐operative IA. In a multivariate model, only the number of pre‐operative IAs was associated with the number of ECs given (OR per IA 1.9, P < 0.05). ABOi kidney transplant recipients have a high postoperative bleeding risk, correlating with the number of pre‐operative IA sessions performed.

22 October 2021 in Transplant International
Verified
Journal Article
Open access
PDF file
AWAnnelies E De Weerd
Annelies E De Weerd
JBJan A. J. G. van Den Brand
Jan A. J. G. van Den Brand
HBHanneke Bouwsma
Hanneke Bouwsma
AVAiko P. J. Vries
Aiko P. J. Vries
IDIne (Ph.) M. M. Dooper
Ine (Ph.) M. M. Dooper
MBMarije C. Baas
Marije C. Baas
Kidney transplant candidates are blood group incompatible with roughly one out of three potential living donors. We compared outcomes after ABO-incompatible (ABOi) kidney transplantation with matched ABO-compatible (ABOc) living and deceased donor transplantation and analyzed different induction regimens. We performed a retrospective study with propensity matching and compared patient and death-censored graft survival after ABOi versus ABOc living donor and deceased donor kidney transplantation in a nationwide registry from 2006 till 2019. 296 ABOi were compared with 1184 center and propensity-matched ABOc living donor and 1184 deceased donor recipients (matching: recipient age, sex, blood group, and PRA). Patient survival was better compared with deceased donor [hazard ratio (HR) for death of HR 0.69 (0.49–0.96)] and non-significantly different from ABOc living donor recipients [HR 1.28 (0.90–1.81)]. Rate of graft failure was higher compared with ABOc living donor transplantation [HR 2.63 (1.72–4.01)]. Rejection occurred in 47% of 140 rituximab versus 22% of 50 rituximab/basiliximab, and 4% of 92 alemtuzumab-treated recipients (P < 0.001). ABOi kidney transplantation is superior to deceased donor transplantation. Rejection rate and graft failure are higher compared with matched ABOc living donor transplantation, underscoring the need for further studies into risk stratification and induction therapy [NTR7587, www.trialregister.nl].

19 January 2024 in Transplantation
Verified
Journal Article
Closed access
AWAnnelies E De Weerd
Annelies E De Weerd
DRDave L. Roelen
Dave L. Roelen
JWJacqueline van de Wetering
Jacqueline van de Wetering
MBMichiel G.H. Betjes
Michiel G.H. Betjes
SHSebastiaan Heidt
Sebastiaan Heidt
MRMarlies E.J. Reinders
Marlies E.J. Reinders
Imlifidase, derived from a Streptococcus pyogenes enzyme, cleaves the entire immunoglobulin G pool within hours after administration in fully cleaved antigen-binding and crystallizable fragments. These cleaved fragments can no longer exert their antibody-dependent cytotoxic functions, thereby creating a window to permit HLA-incompatible kidney transplantation. Imlifidase is labeled, in Europe only, for deceased donor kidney transplantation in highly sensitized patients, whose chances for an HLA-compatible transplant are negligible. This review discusses outcomes of preclinical and clinical studies on imlifidase and describes the phase III desensitization trials that are currently enrolling patients. A comparison is made with other desensitization methods. The review discusses the immunological work-up of imlifidase candidates and especially the “delisting strategy” of antigens that shift from unacceptable to acceptable with imlifidase desensitization. Other considerations for clinical implementation, such as adaptation of induction protocols, are also discussed. Imlifidase cleaves most of the currently used induction agents except for horse antithymocyte globulin, and rebound of donor-specific antibodies should be managed. Another consideration is the timing and interpretation of (virtual) crossmatches when bringing this novel desensitization agent into the clinic.

1 July 2020 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
MZMarieke van der Zwan
Marieke van der Zwan
DHDennis A. Hesselink
Dennis A. Hesselink
EBEsther Brusse
Esther Brusse
PDPieter A. van Doorn
Pieter A. van Doorn
MHMartijn W.F. van Den Hoogen
Martijn W.F. van Den Hoogen
BJBart C. Jacobs
Bart C. Jacobs

26 August 2021 in Transplant International
Verified
Journal Article
Open access
PDF file
RZRegina Zanten
Regina Zanten
AWAnnelies E De Weerd
Annelies E De Weerd
MBMichiel GH Betjes
Michiel GH Betjes
MBMarieken Boer‐Verschragen
Marieken Boer‐Verschragen
EMEmma K. Massey
Emma K. Massey
After kidney transplantation, a strict immunosuppressive medication regimen is necessary for graft survival. However, nonadherence to medication has been shown to occur early after transplantation and to increase over time. Weaning the recipient off dual therapy onto monotherapy in order to reduce immunosuppressive burden may also be a way to promote adherence, although little is known about the impact of such a regimen on fear of rejection. We performed a cohort study on medication adherence and fear of rejection in a randomized, investigator-driven, open-label, single-centre pilot study. Recipients were randomized at 6-months post-transplant to either continue Tacrolimus and Mycophenolate mofetil (TAC/MMF) or to taper MMF at 6 months and discontinue MMF at 9 months (TAC monotherapy). Recipients completed questionnaires about medication adherence and fear of rejection at 6 and 12-months post-transplantation. Medication adherence was significantly higher in the TAC monotherapy group compared to dual TAC/MMF therapy group (χ2 (1) = 4.582; P = 0.032). We found no difference in fear of rejection between the two groups of recipients (P = 0.887). Simplification of the medication regimen is a potential tool for increasing adherence in clinical practice (Netherlands Trial Register – NL4672).